Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Aug 26. pii: S0169-5002(19)30621-X. doi: 10.1016/j.lungcan.2019.08.020. [Epub ahead of print] No abstract available.

PMID:
31492438
2.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA.

Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.

PMID:
31319993
3.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK.

Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24.

PMID:
31231122
4.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA.

Lung Cancer. 2019 Jul;133:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15.

PMID:
31200821
5.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
6.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

Riess JW, Kong CS, West RB, Padda SK, Neal JW, Wakelee HA, Le QT.

Clin Lung Cancer. 2019 May;20(3):e356-e361. doi: 10.1016/j.cllc.2018.12.005. Epub 2018 Dec 21.

PMID:
30773448
7.

Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study.

Huang Y, Chow KKH, Aredo JV, Padda SK, Han SS, Kakusa BW, Hayden Gephart M.

World Neurosurg. 2019 May;125:e487-e496. doi: 10.1016/j.wneu.2019.01.112. Epub 2019 Jan 31.

PMID:
30710723
8.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.

Myall NJ, Henry S, Wood D, Neal JW, Han SS, Padda SK, Wakelee HA.

Clin Lung Cancer. 2019 Mar;20(2):e208-e217. doi: 10.1016/j.cllc.2018.10.003. Epub 2018 Oct 23.

9.

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment.

Charville GW, Padda SK, Sibley RK, Puthillath A, Kwo PY.

Case Reports Hepatol. 2018 Aug 5;2018:3413592. doi: 10.1155/2018/3413592. eCollection 2018.

10.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.

Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic BI, Wakelee HA.

Cancer Chemother Pharmacol. 2018 Sep;82(3):541-550. doi: 10.1007/s00280-018-3646-0. Epub 2018 Jul 20.

PMID:
30030583
11.

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.

Aredo JV, Padda SK.

Curr Treat Options Oncol. 2018 Jun 27;19(8):43. doi: 10.1007/s11864-018-0557-6. Review.

PMID:
29951788
12.

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.

Tseng D, Padda SK, Wakelee HA.

J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008. No abstract available.

13.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors.

Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA.

J Thorac Imaging. 2018 May;33(3):176-183. doi: 10.1097/RTI.0000000000000310.

14.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS.

J Thorac Oncol. 2018 Mar;13(3):436-446. doi: 10.1016/j.jtho.2017.11.118. Epub 2017 Nov 27.

15.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M.

Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.

16.

Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?

Padda SK, Keijzers M, Wakelee HA.

J Thorac Dis. 2016 Aug;8(8):1895-900. doi: 10.21037/jtd.2016.06.77. No abstract available.

17.

Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer.

Padda SK, Harvey RD.

J Adv Pract Oncol. 2016 Apr;7(3):299-301. Epub 2016 Apr 1. Review. No abstract available.

18.

Pruritus as a Paraneoplastic Symptom of Thymoma.

Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ, Loo BW, Neal JW, Hardy R, Wakelee HA.

J Thorac Oncol. 2015 Nov;10(11):e110-2. doi: 10.1097/JTO.0000000000000623. No abstract available.

19.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

Das M, Padda SK, Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelee HA.

Lung Cancer. 2015 Sep;89(3):280-6. doi: 10.1016/j.lungcan.2015.06.011. Epub 2015 Jun 22.

20.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA.

Lung Cancer. 2015 Jan;87(1):34-8. doi: 10.1016/j.lungcan.2014.11.006. Epub 2014 Nov 15.

PMID:
25443273
21.

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA.

J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.

22.

Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.

Padda SK, Burt BM, Trakul N, Wakelee HA.

Semin Oncol. 2014 Feb;41(1):40-56. doi: 10.1053/j.seminoncol.2013.12.011. Epub 2013 Dec 12. Review.

PMID:
24565580
23.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA.

Clin Lung Cancer. 2013 Sep;14(5):592-5. doi: 10.1016/j.cllc.2013.04.008. Epub 2013 Jun 27. No abstract available.

24.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.

Padda SK, Chhatwani L, Zhou L, Jacobs CD, Lopez-Anaya A, Wakelee HA.

Anticancer Drugs. 2013 Aug;24(7):731-5. doi: 10.1097/CAD.0b013e32836100d7.

PMID:
23552470
25.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1013-20. doi: 10.1007/s00280-011-1792-8. Epub 2011 Dec 11.

Supplemental Content

Loading ...
Support Center